ClinicalTrials.gg
CompletedNCT01342796Updated Apr 19, 2021Results posted

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

A Phase 2 interventional study of MF59C.1-adjuvanted subunit influenza vaccine and Sub unit, Inactivated, Influenza vaccine in Seasonal Influenza, Influenza and Influenza Due to Unspecified Influenza Virus, sponsored by Novartis Vaccines. Completed at 2 sites in Belgium. Open to participants aged 6 Months to 36 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-19.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
6 Months to 36 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Influenza, Human by Novartis — none open to participants now, none under way, none of them phase 3. Influenza, Human · Novartis.

Enrollment
81st of 97
84 · median 270
Started
2011
with 4 others
Phase 2
42 of 101
none open now
Registered
77th of 101
by date

Among the 101 studies in Influenza, Human by Novartis, this one is the 81st largest by enrollment of the 97 interventional ones that give a count, is one of 5 that started in 2011, is one of 42 in phase 2, and was the 77th registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

None of the 101 studies in Influenza, Human by Novartis is open now. The open studies under Influenza, Human, anywhere →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 6 Months to 36 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 101 studies in Influenza, Human by Novartis as a file.
02

Study summary

This study aims to evaluate the immunogenicity, by means of cell mediated immunity (CMI) and hemagglutination inhibition (HI) assay, and also the safety of a MF59C.1-adjuvanted subunit influenza vaccine compared with a conventional subunit vaccine in previously unvaccinated children aged 6 to \<36 months.

03

Conditions studied

  • Seasonal Influenza
  • Influenza
  • Influenza Due to Unspecified Influenza Virus
  • Human Influenza

Browse trials for

Keywords

  • Cell mediated immunity
  • cell mediated immune response
  • Children
  • adjuvanted
04

Who can participate

Ages eligible
6 Months to 36 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female previously unvaccinated healthy children aged 6 to \<36 months.

Exclusion criteria

Exclusion Criteria:

  • Any known or suspected impairment of the immune system, any serious disease.
  • Any subjects receiving licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for ) prior to enrollment in this study.
  • Individuals who have had influenza vaccine or documented suspected influenza disease prior to day 1.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Arm 1

    Biological: MF59C.1-adjuvanted subunit influenza vaccine

  • Active comparator
    Arm 2

    Biological: Sub unit, Inactivated, Influenza vaccine

Interventions

  • BiologicalMF59C.1-adjuvanted subunit influenza vaccine

    2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm

  • BiologicalSub unit, Inactivated, Influenza vaccine

    2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm

06

What researchers measure

Primary outcomes

  1. Cell Mediated Immune (CMI) Responses After In-vitro Restimulation Of Peripheral Blood Mononuclear Cells (PBMC) Following Vaccination.

    The CMI responses were determined by intracellular staining/Fluorescence-Activated Cell Sorting(ICS/FACS) after in-vitro restimulation of PBMC with vaccine antigens on day 0 and day 50.

    Time frame: Day 1, Day 50

  2. Number of Subjects Reporting Unsolicited Adverse Events After Receiving Two Doses of aTIV and TIV

    The number of subjects reporting unsolicited AEs between Day 1 and the study termination i.e., Day 50, after receiving two doses of aTIV and TIV. Data are reported based on the Safety Set.

    Time frame: Day 1 to Day 50 post vaccination

Secondary outcomes

  1. Percentage of Subjects Achieving Seroconversion or Significant Increase in HI Titer

    To evaluate the immune responses by seroconversion of aTIV or TIV according to CHMP criteria for seasonal influenza vaccines as determined by hemagglutination inhibition (HI) test on plasma from previously unvaccinated healthy children aged 6 to \< 36 months for all three strains. Criteron: The proportion of subjects achieving seroconversion or significant increase in HI titer should be \> 40%.

    Time frame: Day 50

  2. Geometric Mean Ratios (GMR)

    To evaluate the immune responses by mean geometric increase (GMR) of aTIV or TIV according to CHMP criteria for seasonal influenza vaccines as determined by hemagglutination inhibition (HI) test on plasma from previously unvaccinated healthy children aged 6 to \< 36 months for all three strains. Criterion: Mean geometric increase (GMR) should be \> 2.5.

    Time frame: Day 50/Day 1

  3. Percentage of Subjects With HI Titers >1:40

    To evaluate the immune responses by proportion of subjects with HI titers \>1:40 of aTIV or TIV according to CHMP criteria for seasonal influenza vaccines as determined by hemagglutination inhibition (HI) test on plasma from previously unvaccinated healthy children aged 6 to \< 36 months for all three strains. Criterion: The proportion of subjects with HI titers \>1:40 should be \> 70%

    Time frame: Day 50

07

Results

Posted Apr 19, 2021

Participant flow

Subjects were recruited from two sites in Belgium.

Participant flow — Overall Study
MilestoneaTIV GroupTIV Group
Started4341
Completed4038
Not completed33
Withdrew: Withdrawal by subject20
Withdrew: Lost to follow-up03
Withdrew: Inappropriate enrollment10

Outcome measures

PrimaryCell Mediated Immune (CMI) Responses After In-vitro Restimulation Of Peripheral Blood Mononuclear Cells (PBMC) Following Vaccination.

The CMI responses were determined by intracellular staining/Fluorescence-Activated Cell Sorting(ICS/FACS) after in-vitro restimulation of PBMC with vaccine antigens on day 0 and day 50.

Time frame:
Day 1, Day 50
Reported as:
Mean · Cells per Million Total Cells
Cell Mediated Immune (CMI) Responses After In-vitro Restimulation Of Peripheral Blood Mononuclear Cells (PBMC) Following Vaccination.
Cells per Million Total CellsaTIV GroupTIV Group
Any Cytokine - A/H1N1, Day 1631 (477 to 784)655 (503 to 806)
Any Cytokine - A/H1N1, Day 501560 (1244 to 1876)1137 (826 to 1449)
Any Cytokine - A/H3N2, Day 1503 (346 to 660)462 (322 to 602)
Any Cytokine - A/H3N2, Day 501328 (1105 to 1550)671 (474 to 869)
Any Cytokine - B/Brisbane, (N=19, 24), Day 1648 (452 to 844)753 (579 to 927)
Any Cytokine - B/Brisbane, Day 502369 (1940 to 2798)1062 (677 to 1446)
Any cytokine - B/Florida, Day 1605 (215 to 996)749 (483 to 1015)
Any cytokine - B/Florida, Day 501607 (1113 to 2100)996 (662 to 1330)
Any Cytokine - SEB, Day 177048 (55913 to 98182)107200 (91682 to 122719)
Any Cytokine - SEB, Day 5080400 (56864 to 103935)105013 (88270 to 121755)
Any cytokine -Tetanus toxoid, Day 11246 (639 to 1852)1368 (914 to 1822)
Any cytokine -Tetanus toxoid, Day 501162 (759 to 1565)1229 (928 to 1531)
IL-2- A/H1N1, Day 1283 (207 to 359)240 (165 to 315)
IL-2- A/H1N1, Day 501141 (858 to 1423)642 (366 to 918)
IL-2 - A/H3N2, Day 1212 (140 to 283)184 (121 to 248)
IL-2 - A/H3N2, Day 50925 (723 to 1126)387 (208 to 566)
IL-2- B/Brisbane, Day 1301 (183 to 419)330 (225 to 435)
IL-2- B/Brisbane, Day 501704 (1321 to 2087)610 (267 to 954)
IL-2 - B/Florida, Day 1375 (119 to 632)275 (100 to 449)
IL-2 - B/Florida, Day 501094 (691 to 1497)541 (268 to 813)
IL-2 - SEB, Day 167524 (47735 to 87313)93312 (78781 to 107843)
IL-2 - SEB, Day 5067357 (46682 to 88033)92489 (77768 to 107210)
IL-2 - Tetanus toxoid, Day 1604 (309 to 899)672 (451 to 892)
IL-2 - Tetanus toxoid, Day 50659 (291 to 1027)765 (489 to 1041)
IFN-γ - A/H1N1, Day 192 (49 to 135)116 (73 to 158)
IFN-γ - A/H1N1, Day 50257 (163 to 350)248 (156 to 340)
IFN-γ - A/H3N2, Day 178 (44 to 112)78 (48 to 108)
IFN-γ - A/H3N2, Day 50191 (113 to 268)130 (61 to 199)
IFN-γ -B/Brisbane, Day 183 (37 to 130)122 (81 to 163)
IFN-γ -B/Brisbane, Day 50331 (201 to 462)106 (-12.1 to 224)
IFN-γ - B/Florida, Day 1112 (46 to 179)94 (49 to 139)
IFN-γ - B/Florida, Day 50193 (67 to 320)145 (59 to 230)
IFN-γ - SEB, Day 13615 (2110 to 5120)4780 (3675 to 5885)
IFN-γ - SEB, Day 503858 (2367 to 5349)4519 (3390 to 5649)
IFN-γ - Tetanus toxoid, Day 1156 (64 to 248)148 (80 to 217)
IFN-γ - Tetanus toxoid, Day 5074 (4 to 144)163 (10 to 215)
TNF-α- A/H1N1, Day 1128 (87 to 170)133 (92 to 174)
TNF-α- A/H1N1, Day 50495 (368 to 621)290 (165 to 415)
TNF-α - A/H3N2, Day 181 (56 to 106)69 (46 to 91)
TNF-α - A/H3N2, Day 50447 (324 to 571)202 (93 to 311)
TNF-α - B/Brisbane, Day 1116 (62 to 170)152 (104 to 200)
TNF-α - B/Brisbane, Day 50921 (658 to 1184)251 (13 to 490)
TNF-α - B/Florida, Day 1149 (50 to 249)171 (103 to 238)
TNF-α - B/Florida, Day 50614 (372 to 857)244 (77 to 410)
TNF-α-SEB, Day 125467 (15528 to 35406)37856 (30559 to 45154)
TNF-α-SEB, Day 5032510 (22453 to 42566)34805 (27557 to 42054)
TNF-α-Tetanus toxoid, Day 1537 (278 to 795)541 (348 to 735)
TNF-α-Tetanus toxoid, Day 50384 (156 to 612)644 (473 to 815)
IL-13 - A/H1N1, Day 1232 (132 to 332)170 (71 to 268)
IL-13 - A/H1N1, Day 50242 (105 to 378)347 (212 to 483)
IL-13 - A/H3N2, Day 1250 (154 to 346)174 (89 to 259)
IL-13 - A/H3N2, Day 50361 (229 to 494)231 (114 to 348)
IL-13 - B/Brisbane, Day 1184 (59 to 308)168 (57 to 278)
IL-13 - B/Brisbane, Day 50346 (228 to 463)221 (116 to 326)
IL-13 - B/Florida, Day 1150 (-27.62 to 329)88 (-33.78 to 209)
IL-13 - B/Florida, Day 5097 (18 to 175)93 (39 to 146)
IL-13 -SEB, Day 11017 (547 to 1487)950 (605 to 1295)
IL-13 -SEB, Day 50772 (391 to 1153)993 (714 to 1272)
IL-13 -Tetanus toxoid, Day 1166 (-0.845 to 333)222 (98 to 347)
IL-13 -Tetanus toxoid, Day 50247 (-21.88 to 516)293 (94 to 491)
PrimaryNumber of Subjects Reporting Unsolicited Adverse Events After Receiving Two Doses of aTIV and TIV

The number of subjects reporting unsolicited AEs between Day 1 and the study termination i.e., Day 50, after receiving two doses of aTIV and TIV. Data are reported based on the Safety Set.

Time frame:
Day 1 to Day 50 post vaccination
Reported as:
Count of participants · Participants
Number of Subjects Reporting Unsolicited Adverse Events After Receiving Two Doses of aTIV and TIV
ParticipantsaTIV GroupTIV Group
Any Adverse Event (AE)2018
At least possibly related AE13
Any SAE02
At least possibly related SAE00
AE leading to discontinuation00
Death00
SecondaryPercentage of Subjects Achieving Seroconversion or Significant Increase in HI Titer

To evaluate the immune responses by seroconversion of aTIV or TIV according to CHMP criteria for seasonal influenza vaccines as determined by hemagglutination inhibition (HI) test on plasma from previously unvaccinated healthy children aged 6 to \< 36 months for all three strains. Criteron: The proportion of subjects achieving seroconversion or significant increase in HI titer should be \> 40%.

Time frame:
Day 50
Reported as:
Number · Percentage of participants
Percentage of Subjects Achieving Seroconversion or Significant Increase in HI Titer
Percentage of participantsaTIV GroupTIV Group
A/H1N1/California100 (86 to 100)73 (54 to 88)
A/H3N2/Victoria100 (86 to 100)93 (78 to 99)
B/Brisbane100 (86 to 100)53 (34 to 72)
SecondaryGeometric Mean Ratios (GMR)

To evaluate the immune responses by mean geometric increase (GMR) of aTIV or TIV according to CHMP criteria for seasonal influenza vaccines as determined by hemagglutination inhibition (HI) test on plasma from previously unvaccinated healthy children aged 6 to \< 36 months for all three strains. Criterion: Mean geometric increase (GMR) should be \> 2.5.

Time frame:
Day 50/Day 1
Reported as:
Geometric mean · titer ratio
Geometric Mean Ratios (GMR)
titer ratioaTIV GroupTIV Group
A/H1N1/California41 (23 to 74)9.99 (5.87 to 17)
A/H3N2/Victoria199 (130 to 303)35 (24 to 51)
B/Brisbane34 (22 to 52)5.63 (3.83 to 8.29)
SecondaryPercentage of Subjects With HI Titers >1:40

To evaluate the immune responses by proportion of subjects with HI titers \>1:40 of aTIV or TIV according to CHMP criteria for seasonal influenza vaccines as determined by hemagglutination inhibition (HI) test on plasma from previously unvaccinated healthy children aged 6 to \< 36 months for all three strains. Criterion: The proportion of subjects with HI titers \>1:40 should be \> 70%

Time frame:
Day 50
Reported as:
Number · Percentage of participants
Percentage of Subjects With HI Titers >1:40
Percentage of participantsaTIV GroupTIV Group
A/H1N1/California100 (86 to 100)93 (78 to 99)
A/H3N2/Victoria100 (86 to 100)97 (83 to 100)
B/Brisbane100 (86 to 100)57 (37 to 75)

Adverse events

Collected over All solicited AEs and unsolicited AEs were collected from Day 1 to Day 7; all unsolicited SAEs, medically attended AEs, AEs leading to withdrawal from the study were collected from Day 1 to Day 50.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
aTIV (6 to <36 Months)—0/43 (0%)37/43 (86%)
TIV (6 to <36 Months)—2/41 (4.9%)29/41 (70.7%)
Most frequent serious events
Most frequent serious events
EventaTIV (6 to <36 Months)TIV (6 to <36 Months)
VaricellaInfections and infestations0/431/41
PneumoniaInfections and infestations0/431/41
Most frequent other events
Showing 10 of 13
Most frequent other events
EventaTIV (6 to <36 Months)TIV (6 to <36 Months)
PyrexiaGeneral disorders19/4315/41
SomnolenceNervous system disorders11/4312/41
Eating DisorderPsychiatric disorders11/4311/41
DiarrhoeaGastrointestinal disorders11/4311/41
Injection site painGeneral disorders11/439/41
IrratabilityPsychiatric disorders11/437/41
Injection site erythemaGeneral disorders8/432/41
CryingGeneral disorders6/437/41
VomitingGastrointestinal disorders3/435/41
NasopharyngitisGeneral disorders5/434/41

Baseline characteristics

Age, Continuous
Age, Continuous(years)aTIV GroupTIV GroupTotal
Mean20.2 ± 8.521.4 ± 9.720.8 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)aTIV GroupTIV GroupTotal
Female201434
Male232750
08

Study locations

2 sites
  • Site 21: GZA campus Sint Vincentius
    Antwerpen, 2018, Belgium
  • Site 22: Kinderartsenpraktijk
    Hasselt, 3500, Belgium
09

References and documents

Publications

  • Zedda L, Forleo-Neto E, Vertruyen A, Raes M, Marchant A, Jansen W, Clouting H, Arora A, Beatty ME, Galli G, Del Giudice G, Castellino F. Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age. Pediatr Infect Dis J. 2015 Jan;34(1):73-8. doi: 10.1097/INF.0000000000000465. PubMed 25037034 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2021, 9 years 2 months after primary completion. A results delay was requested in Aug 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2011
First posted
Apr 27, 2011
Start
May 2011
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results delay requested
Aug 23, 2012
Results first posted
Apr 19, 2021
Last update
Apr 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01342796
Lead sponsor
Novartis Vaccines
Responsible party
Sponsor
First posted
Apr 27, 2011
Start date
May 2011
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Apr 19, 2021
Last update
Apr 19, 2021
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion